FFM
IKT icon

Fairmount Funds Management’s Inhibikase Therapeutics IKT Stock Holding History

Fairmount Funds Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5M Hold
8,625,000
– – 1.16% 12
2026
Q1 		$14.5M Hold
8,625,000
– – 1.05% 12
2025
Q4 		$17.7M Buy
8,625,000
+2,500,000
+41% +$3.98M 1.35% 13
2025
Q3 		$9.92M Hold
6,125,000
– – 0.89% 17
2025
Q2 		$11.9M Hold
6,125,000
– – 1.55% 16
2025
Q1 		$13.4M Hold
6,125,000
– – 2.08% 14
2024
Q4 		$19.9M Buy
+6,125,000
New +$15.3M 1.98% 16

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fairmount Funds Management's IKT Position: Q2 2026 in Review

Fairmount Funds Management held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 8,625,000 shares worth $17.5M. The position accounts for 1.16% of the portfolio, ranked #12.

Fairmount Funds Management first reported a position in IKT in Q4 2024 and has held it in 7 quarters since. The position peaked at $19.9M in Q4 2024. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Fairmount Funds Management held 8,625,000 shares of Inhibikase Therapeutics worth $17.5M as of Q2 2026.
  • Fairmount Funds Management left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up 1.16% of Fairmount Funds Management's portfolio in Q2 2026, its #12 holding.
  • Fairmount Funds Management first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Fairmount Funds Management's Inhibikase Therapeutics position peaked at $19.9M in Q4 2024.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.